

Elaine A Dunlop

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6802361/publications.pdf>

Version: 2024-02-01

25
papers

6,939
citations

430874

18
h-index

610901

24
g-index

29
all docs

29
docs citations

29
times ranked

17515
citing authors

#	ARTICLE	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). <i>Autophagy</i> , 2016, 12, 1-222.	9.1	4,701
2	mTOR and autophagy: A dynamic relationship governed by nutrients and energy. <i>Seminars in Cell and Developmental Biology</i> , 2014, 36, 121-129.	5.0	382
3	Mammalian target of rapamycin complex 1: Signalling inputs, substrates and feedback mechanisms. <i>Cellular Signalling</i> , 2009, 21, 827-835.	3.6	220
4	A tuberous sclerosis complex signalling node at the peroxisome regulates mTORC1 and autophagy in response to ROS. <i>Nature Cell Biology</i> , 2013, 15, 1186-1196.	10.3	218
5	mTOR Ser-2481 Autophosphorylation Monitors mTORC-specific Catalytic Activity and Clarifies Rapamycin Mechanism of Action. <i>Journal of Biological Chemistry</i> , 2010, 285, 7866-7879.	3.4	189
6	ULK1 inhibits mTORC1 signaling, promotes multisite Raptor phosphorylation and hinders substrate binding. <i>Autophagy</i> , 2011, 7, 737-747.	9.1	177
7	Control of TSC2-Rheb signaling axis by arginine regulates mTORC1 activity. <i>ELife</i> , 2016, 5, .	6.0	147
8	The lysosome: a crucial hub for AMPK and mTORC1 signalling. <i>Biochemical Journal</i> , 2017, 474, 1453-1466.	3.7	143
9	The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation. <i>Journal of Clinical Investigation</i> , 2014, 124, 2640-2650.	8.2	124
10	The kinase triad, AMPK, mTORC1 and ULK1, maintains energy and nutrient homeostasis. <i>Biochemical Society Transactions</i> , 2013, 41, 939-943.	3.4	109
11	Erythropoietin Receptor Expression in Non-Small Cell Lung Carcinoma: A Question of Antibody Specificity. <i>Stem Cells</i> , 2007, 25, 718-722.	3.2	86
12	Mammalian target of rapamycin complex 1-mediated phosphorylation of eukaryotic initiation factor 4E-binding protein 1 requires multiple protein-protein interactions for substrate recognition. <i>Cellular Signalling</i> , 2009, 21, 1073-1084.	3.6	72
13	Absence of the Birt-Hogg-Dub gene product is associated with increased hypoxia-inducible factor transcriptional activity and a loss of metabolic flexibility. <i>Oncogene</i> , 2011, 30, 1159-1173.	5.9	69
14	FLCN, a novel autophagy component, interacts with GABARAP and is regulated by ULK1 phosphorylation. <i>Autophagy</i> , 2014, 10, 1749-1760.	9.1	64
15	Erythropoietin-Induced Activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK Pathways Promotes Malignant Cell Behavior in a Modified Breast Cancer Cell Line. <i>Molecular Cancer Research</i> , 2010, 8, 615-626.	3.4	61
16	Induction of Signalling in Non-Erythroid Cells by Pharmacological Levels of Erythropoietin. <i>Neurodegenerative Diseases</i> , 2006, 3, 94-100.	1.4	52
17	Assessment of the potential pathogenicity of missense mutations identified in the GTPase-activating protein (GAP)-related domain of the neurofibromatosis type-1 (<i>NF1</i>) gene. <i>Human Mutation</i> , 2012, 33, 1687-1696.	2.5	21
18	Rab35-dependent extracellular nanovesicles are required for induction of tumour supporting stroma. <i>Nanoscale</i> , 2018, 10, 8547-8559.	5.6	20

#	ARTICLE	IF	CITATIONS
19	Impaired Downregulation Following Erythropoietin Receptor Activation in Non-Small Cell Lung Carcinoma. <i>Stem Cells</i> , 2007, 25, 380-384.	3.2	18
20	Tuberous sclerosisâ€™A model for tumour growth. <i>Seminars in Cell and Developmental Biology</i> , 2016, 52, 3-11.	5.0	18
21	Targeting protein homeostasis with nelfinavir/salinomycin dual therapy effectively induces death of mTORC1 hyperactive cells. <i>Oncotarget</i> , 2017, 8, 48711-48724.	1.8	13
22	Mechanistic target of rapamycin inhibitors: successes and challenges as cancer therapeutics. , 2019, 2, 1069-1085.		11
23	Loss of tuberous sclerosis complex 2 sensitizes tumors to nelfinavirâ€™bortezomib therapy to intensify endoplasmic reticulum stress-induced cell death. <i>Oncogene</i> , 2018, 37, 5913-5925.	5.9	10
24	Determining the pathogenicity of patient-derived TSC2 mutations by functional characterization and clinical evidence. <i>European Journal of Human Genetics</i> , 2011, 19, 789-795.	2.8	9
25	Energy Stress-Mediated Cytotoxicity in Tuberous Sclerosis Complex 2-Deficient Cells with Nelfinavir and Mefloquine Treatment. <i>Cancers</i> , 2018, 10, 375.	3.7	5